Invivyd, Inc. Files 8-K: Voting Matters & Financials
Ticker: IVVD · Form: 8-K · Filed: May 22, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | May 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, sec-filing
TL;DR
Invivyd filed an 8-K covering voting, Reg FD, and financials as of May 21.
AI Summary
Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on May 22, 2024, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements and exhibits as of May 21, 2024. The company, incorporated in Delaware, is in the biological products sector and is headquartered in Waltham, MA.
Why It Matters
This filing provides updates on corporate governance and financial reporting, which are crucial for investors to assess the company's operational status and decision-making processes.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, primarily reporting on corporate actions and financial disclosures without announcing significant new events.
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Adagio Therapeutics, Inc. (company) — Former company name
- May 21, 2024 (date) — Date of earliest event reported
- May 22, 2024 (date) — Filing date
- Waltham, MA (location) — Principal executive offices location
FAQ
What specific matters were submitted to a vote of Invivyd's security holders?
The filing indicates that matters were submitted to a vote, but the specific details of these matters are not provided in the excerpt.
What is the primary business of Invivyd, Inc.?
Invivyd, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
When did Invivyd, Inc. change its name from Adagio Therapeutics, Inc.?
The date of the name change from Adagio Therapeutics, Inc. to Invivyd, Inc. was November 12, 2020.
What is Invivyd's principal executive office address?
Invivyd's principal executive offices are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
What is the Commission File Number for Invivyd, Inc.?
The Commission File Number for Invivyd, Inc. is 001-40703.
Filing Stats: 641 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-05-22 07:06:33
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
Filing Documents
- ivvd-20240521.htm (8-K) — 73KB
- ivvd-ex99_1.htm (EX-99.1) — 21KB
- img59752938_0.jpg (GRAPHIC) — 84KB
- 0000950170-24-063279.txt ( ) — 338KB
- ivvd-20240521.xsd (EX-101.SCH) — 31KB
- ivvd-20240521_htm.xml (XML) — 5KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders. On May 21, 2024, Invivyd, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). The following is a summary of the matters voted on at the Annual Meeting and the final voting results as certified by the Company's independent inspector of election in connection with the Annual Meeting. Proposal 1: The stockholders of the Company elected Tamsin Berry, Sara Cotter, Marc Elia, Srishti Gupta, M.D., Christine Lindenboom, Terrance McGuire and Kevin McLaughlin as directors for a one-year term expiring at the Company's 2025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. The votes were cast as follows: Nominee For Withheld Broker Non-Votes Tamsin Berry 92,449,521 1,846,310 4,571,326 Sara Cotter 84,043,272 10,252,559 4,571,326 Marc Elia 83,804,089 10,491,742 4,571,326 Srishti Gupta, M.D. 84,040,591 10,255,240 4,571,326 Christine Lindenboom 83,021,013 11,274,818 4,571,326 Terrance McGuire 91,427,314 2,868,517 4,571,326 Kevin McLaughlin 92,450,615 1,845,216 4,571,326 Proposal 2: The stockholders of the Company ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, with votes cast as follows: For Against Abstain Broker Non-Votes 98,709,273 90,855 67,029 —
01
Item 7.01. Regulation FD Disclosure. On May 22, 2024, the Company issued a press release entitled "Invivyd Elects Two New Independent Members to its Board of Directors." A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference in this Item 7.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated May 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: May 22, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary